August 15, , by NCI Staff. Women who had cancer cells detected in their blood 5 years after a breast cancer diagnosis were 13 times more likely to have their cancer return than women who did not, results from an ongoing study have shown. Most women who are diagnosed with hormone receptor—positive breast cancer that has not spread will not have a recurrence. Among those who do have a recurrence, more than half have a late recurrence, meaning their disease will return 5 or more years after diagnosis. Doctors do not currently have a reliable method to predict who is likely to have a late recurrence and is a candidate for therapies that might prevent or delay it. According to the study findings, a blood test—a type of liquid biopsy —may help classify patients according to their recurrence risk.
Liquid Biopsy May Predict Risk of Breast Cancer Returning Years Later
CTC Pros | Canadian Cancer Trials - Trial Details
Radiation treatment to the prostate bed where the prostate used to be is the only form of treatment currently available for patients who have a rising PSA blood test after surgery. A rising PSA test suggests that there are prostate cancer cells left behind in the body, either in the site of the original surgery or elsewhere in the body. Alternatively some men have risk factors after their surgery that predisposes them to have a recurrence of their cancer soon after surgery. You are being asked to participate in this study to see if we can find prostate cancer cells in your blood.
Circulating tumor cell count could help choose treatment for metastatic breast cancer patients
You are viewing the new article page. Let us know what you think. Return to old version. Circulating tumor cells CTCs carry independent prognostic information in patients with metastatic breast cancer MBC on different lines of therapy. We aimed to evaluate whether longitudinal enumeration of circulating tumor cells CTCs and CTC clusters could improve prognostication and monitoring of patients with metastatic breast cancer MBC starting first-line therapy.
Study record managers: refer to the Data Element Definitions if submitting registration or results information. Eligible patients will be randomised in ratio to either the trastuzumab arm or the observation arm. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.